LFBC(SZ:002513)2022-12-05 01:04Group 1: Company Overview - Jiangsu Lanfeng Bio-chemical Co., Ltd. is listed with the stock code 002513 and abbreviated as Lanfeng Biochemical [1] Group 2: Investor Relations Activity - The investor relations activity took place on September 15, 2017, from 14:30 to 16:30 in the company meeting room [2] - The meeting involved a specific audience survey conducted by Haitong Securities with industry researcher Li Zhi [2] Group 3: Product and Sales Information - The main agricultural chemical products include fungicides (e.g., Multi-sterilizing agent, Methyl thiophanate), herbicides (e.g., Cyhalofop-butyl), and insecticides (e.g., Chlorpyrifos) [2] - Sales of Cyhalofop-butyl, Isoprothiolane, and phosgene intermediates are performing well, while sales of Multi-sterilizing agent and Methyl thiophanate are stable [2] Group 4: Strategic Transition to Pharmaceuticals - The company is transitioning towards the pharmaceutical sector due to the cyclical nature, heavy asset requirements, low profit margins, and environmental pollution associated with the agricultural chemical industry [3] - The pharmaceutical industry offers strong anti-cyclical characteristics, lighter assets, and higher profit margins, making it a complementary business model [3] Group 5: Ark Pharmaceutical's Product Line - Ark Pharmaceutical's main products include traditional Chinese medicine and Western medicine for treating Alzheimer's, with notable products being Compound Banzhilan Capsules and Donepezil Hydrochloride Tablets [3] - The market prospects for anti-tumor and anti-aging products are broad due to the aging population in China [3] Group 6: New Factory Construction - Ark Pharmaceutical is investing approximately 200 million RMB to build a new production facility to meet the new GMP certification requirements, expected to be submitted by May 2018 [3] - The new facility is designed to high technical standards, enhancing operational management and risk prevention [3] Group 7: Future Acquisition Plans - The company has completed a two-month period without planning any major asset restructuring and remains committed to its strategic transition towards pharmaceuticals [4] - The company aims to seek synergistic and performance-supported pharmaceutical companies for acquisition to ensure long-term stable development [4]